Registry to assess adverse events from ablative radiotherapy in metastatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a registry of patients undergoing ablative radiotherapy for metastatic disease. It focuses on collecting data to evaluate the rates of acute adverse events associated with this treatment approach. Participants must be at least 18 years old and have radiographic evidence of metastatic disease, with plans to receive or having received hypofractionated image-guided radiotherapy. The study will help in understanding the safety profile of this treatment modality in a real-world setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years of age
* Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
* Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
* Patient must sign study-specific informed consent

Exclusion Criteria:

• None

Where it's running

• Duke Cancer Institute Cary
  Cary, North Carolina, United States Recruiting
• Durham Veterans Administration Health Care System (DVAHCS)
  Durham, North Carolina, United States Recruiting
• Duke University Medical Center
  Durham, North Carolina, United States Recruiting
• Duke Women's Cancer Care Raleigh
  Raleigh, North Carolina, United States Recruiting
• Duke Raleigh Hospital
  Raleigh, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Joseph Salama, MD — Duke University
• Study coordinator: Clinical Trials Office
• Email: RadOnc-Clinical_Trials@dm.duke.edu
• Phone: (919) 668 3726

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for recurrent prostate cancer with metastases

  This study is testing whether combining hormone therapy with targeted radiation or surgery can help men with recurrent prostate cancer live longer without their cancer spreading.

  Recruiting Phase 3 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT05352178

• IL-15–Enhanced NK Cell Therapy for Solid Tumors

  A first-in-human, early-phase study tests whether IL-15–enhanced engineered NK cells are safe and can show early signs of effect in adults with relapsed or metastatic solid tumors.

  Recruiting Early Phase 1 Genovn Therapeutics PTE. LTD. · Chongqing · NCT07621471

• LATTICE radiotherapy vs moderately dose-escalated palliative radiation for metastases

  This study tests whether LATTICE radiotherapy given in 5 fractions works better than a standard palliative dose for patients with metastatic cancer who have 1–2 sizable tumors.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07594431

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

• Adding targeted stereotactic body radiation therapy to standard systemic treatment for people with oligometastatic urothelial (bladder) carcinoma.

  This study will test whether adding stereotactic body radiation therapy (SBRT) to usual systemic treatment helps people with urothelial (bladder) cancer who have up to three extracranial metastases.

  Recruiting Istituto Clinico Humanitas · Rozzano, Milan · NCT07413523

• Stereotactic body radiotherapy for extracranial oligometastatic breast cancer

  This project sees if stereotactic body radiotherapy (SBRT) helps control cancer and extend survival in adults with extracranial oligometastatic breast cancer.

  Recruiting at 9 sites Istituto Clinico Humanitas · Benevento, Benevento and 27 other locations · NCT07397585

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.